← Back to Search

PD-1 Inhibitor

Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

Phase 2

Waitlist Available

Led By Corey Langer, MD

Research Sponsored by Abramson Cancer Center of the University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is testing an experimental drug, pembrolizumab, to see how well it works in treating people with a specific type of lung cancer.

Eligible Conditions

Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression Free Survival (PFS)

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183

21%

Fatigue

13%

Nausea

11%

Back pain

Shortness of Breath

Anemia

Abdominal pain

Diarrhea

Pneumonia

Kidney Injury and/or Infection

Dyspnea

Weight Loss

Malnutrition, Hypercalcemia and Weakness

Pneumothorax

Intractable pain, back pain, hip pain

Activated partial thromboplastin time prolonged

Pleural effusion

Atrial fibrillation with rapid ventricular response

Thrombocytopenia

Respiratory failure

Skin rash

colitis

100%

80%

60%

40%

20%

Study treatment Arm

Single Arm

Trial Design

1Treatment groups

Experimental Treatment

Group I: PembrolizumabExperimental Treatment1 Intervention

Pembrolizumab 200 mg every 3 weeks

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2010

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor

359 Previous Clinical Trials

105,044 Total Patients Enrolled

1 Trials studying Non-small Cell Lung Cancer (NSCLC)

100 Patients Enrolled for Non-small Cell Lung Cancer (NSCLC)

Abramson Cancer Center at Penn MedicineLead Sponsor

387 Previous Clinical Trials

145,644 Total Patients Enrolled

1 Trials studying Non-small Cell Lung Cancer (NSCLC)

100 Patients Enrolled for Non-small Cell Lung Cancer (NSCLC)

Corey Langer, MDPrincipal InvestigatorAbramson Cancer Center at Penn Medicine

5 Previous Clinical Trials

251 Total Patients Enrolled

Media Library

Pembrolizumab (PD-1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02316002 — Phase 2

Non-small Cell Lung Cancer (NSCLC) Research Study Groups: Pembrolizumab

Non-small Cell Lung Cancer (NSCLC) Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT02316002 — Phase 2

Pembrolizumab (PD-1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02316002 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What additional research has been conducted utilizing Pembrolizumab?

"At present, 963 trials are being conducted to research the efficacy of pembrolizumab. Of these studies, 122 have made it through Phase 3 and into active recruitment. The majority of sites studying this medication are located in Houston, Texas; however there are over 36000 additional locations running experiments with pembrolizumab."

Answered by AI

Are researchers still accepting applications for this experiment?

"Presently, this clinical trial is not actively recruiting. The posting for the study was created on January 21st 2015 and last updated December 1st 2022. If you are looking to enroll in other research studies, there are 1917 trials searching for participants with lung cancer and 963 investigations using Pembrolizumab currently accepting enrollees."

Answered by AI

What is the total number of individuals participating in this experiment?

"This research opportunity has since concluded, with the initial posting occurring on January 21st 2015 and the latest edit being made on December 1st 2022. For those who are searching for alternate trials, there are 1917 studies actively recruiting participants suffering from lung cancer and 963 clinical studies involving Pembrolizumab that require enrolment."

Answered by AI

Are there any adverse effects associated with Pembrolizumab treatment?

"Taking into account the Phase 2 trial data, our Power team assigns pembrolizumab a safety score of 2. This suggests that initial evidence on this medication's safety exists but there is yet to be any proof demonstrating efficacy in treating patients."

Answered by AI